CN102586323A - 靶向免疫融合蛋白的构建、表达和纯化方法 - Google Patents
靶向免疫融合蛋白的构建、表达和纯化方法 Download PDFInfo
- Publication number
- CN102586323A CN102586323A CN2011104630919A CN201110463091A CN102586323A CN 102586323 A CN102586323 A CN 102586323A CN 2011104630919 A CN2011104630919 A CN 2011104630919A CN 201110463091 A CN201110463091 A CN 201110463091A CN 102586323 A CN102586323 A CN 102586323A
- Authority
- CN
- China
- Prior art keywords
- dhfr
- pci
- vci
- carrier
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 54
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 239000000047 product Substances 0.000 claims description 36
- 108091008146 restriction endonucleases Proteins 0.000 claims description 35
- 238000012408 PCR amplification Methods 0.000 claims description 32
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 24
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000001042 affinity chromatography Methods 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 238000005571 anion exchange chromatography Methods 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 108010074109 interleukin-22 Proteins 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 101150074155 DHFR gene Proteins 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 239000003636 conditioned culture medium Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 239000012515 MabSelect SuRe Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 11
- 239000013604 expression vector Substances 0.000 abstract description 4
- 238000010276 construction Methods 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 229940125645 monoclonal antibody drug Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- -1 thinner Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110463091.9A CN102586323B (zh) | 2011-07-22 | 2011-12-18 | 靶向免疫融合蛋白的构建、表达和纯化方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110207226 | 2011-07-22 | ||
CN201110207226.5 | 2011-07-22 | ||
CN201110463091.9A CN102586323B (zh) | 2011-07-22 | 2011-12-18 | 靶向免疫融合蛋白的构建、表达和纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102586323A true CN102586323A (zh) | 2012-07-18 |
CN102586323B CN102586323B (zh) | 2014-03-26 |
Family
ID=46475547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110463091.9A Active CN102586323B (zh) | 2011-07-22 | 2011-12-18 | 靶向免疫融合蛋白的构建、表达和纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102586323B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135555A1 (zh) * | 2018-12-28 | 2020-07-02 | 长春金赛药业股份有限公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1657628A (zh) * | 2004-02-19 | 2005-08-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种高效筛选目的蛋白的表达载体,其制备方法及用途 |
-
2011
- 2011-12-18 CN CN201110463091.9A patent/CN102586323B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1657628A (zh) * | 2004-02-19 | 2005-08-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种高效筛选目的蛋白的表达载体,其制备方法及用途 |
Non-Patent Citations (4)
Title |
---|
《中国优秀硕士学位论文全文数据库医药卫生科技辑》 20071015 施明 抗ErbB2 scFv-Fc-IL-2融合蛋白的构建、表达及其功能的初步研究 , 第4期 * |
施明: "抗ErbB2 scFv-Fc-IL-2融合蛋白的构建、表达及其功能的初步研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
杨欣等: "新型人白细胞介素-2(125-Ser)表达载体的构建和大肠杆菌中的表达", 《预防医学情报杂志》 * |
金光泽等: "重组融合人血清白蛋白-人白介素-2C125A突变体在毕赤酵母中的表达", 《食品与生物技术学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135555A1 (zh) * | 2018-12-28 | 2020-07-02 | 长春金赛药业股份有限公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102586323B (zh) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6484634B2 (ja) | Il−15ヘテロ二量体タンパク質及びその用途 | |
ES2828037T3 (es) | Complejo de proteína interleuquina-15 y utilización del mismo | |
CN105121474B9 (zh) | 融合免疫调节蛋白及其制备方法 | |
CN110699327B (zh) | 杂交瘤细胞株6f9、抗体及其应用 | |
CN102850458A (zh) | 新型重组双功能融合蛋白及其制法和用途 | |
WO2022100741A1 (zh) | 人血清白蛋白与白介素2的融合蛋白及其用途 | |
CN110713983B (zh) | 一种表达透明质酸酶的免疫细胞及其应用 | |
CN107236046B (zh) | 一种重组人内皮抑素融合蛋白及其制备方法和应用 | |
CN102586323B (zh) | 靶向免疫融合蛋白的构建、表达和纯化方法 | |
CN111961135A (zh) | 一种用于预防或治疗癌症的抗体 | |
JP5227028B2 (ja) | インターロイキン−2の中和能を有する免疫治療用製剤 | |
CN101475640B (zh) | 一种偶联物及其制备方法与应用 | |
CN103172741B (zh) | 全人源抗egfr抗体 | |
CN1966684B (zh) | 一种新的HER2/neu mRNA体外转录载体的构建及其用途 | |
CA2599150A1 (en) | Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197 | |
CN113896804B (zh) | 嵌合抗原受体(car)及其应用 | |
CN102212135A (zh) | 一种抗血管内皮生长因子的单克隆抗体及应用 | |
CN117143254B (zh) | 一种嵌合抗原受体(car)以及在抗癌中的应用 | |
CN102321178B (zh) | 一种新的促性腺激素释放激素导向融合蛋白突变体 | |
CN116057071B (zh) | 重组灵芝免疫调节蛋白新突变体及其应用 | |
CN114014938B (zh) | 一种嵌合抗原受体(car)及其应用 | |
CN116606884B (zh) | 一种制备car-t细胞的方法以及制得的car-t细胞及其应用 | |
US20230287135A1 (en) | Multifunctional antibody, preparation for same, and uses thereof | |
WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
CN1141318C (zh) | 人促血液血管细胞生成素及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant before: Changchun Genscience Pharmaceuticals Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHANGCHUN GENSCI PHARMACEUTICAL CO., LTD. TO: JINSAI MEDICINE CO., LTD., CHANGCHUN |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Changchun Genscience Pharmaceuticals Co., Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Patentee before: Jinsai Drug Co., Ltd., Changchun |
|
CP03 | Change of name, title or address | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Changchun Genscience Pharmaceuticals Co., Ltd. |